Richard B. Davis, Associate

Publications and Presentations

08/04/21 – Presentation

Susan Brichler Trujillo

"2021 Pharmacy Law Symposium"Quarles & Brady SeminarSusan Brichler Trujillo, John L. Barlament, Christopher T. Dang, Lindsey W. Davis, Simone Colgan Dunlap, Nicholas H. Meza, Meghan C. O'Connor, Theodore M. Sullivan, Richard B. Davis, Katea M. Ravega, Shamika L. Mazyck, Mark W. Bina, Hector J. Diaz, Randall R. Fearnow, Edward D. Rickert, Roger N. MorrisFor the seventh consecutive year, Quarles & Brady's Pharmacy Law Symposium brought together industry leaders to discuss the latest and emerging trends. The ever-changing and important topics discussed included:  Telepharmacy 340B Hot topics in pharmacy law Board of Pharmacy panel discussion with board counsel and... Read More

04/07/21 – Newsletter New Wisconsin Law Regulates PBM and Other Stakeholders Involved in Drug Pricing Health and Life Sciences Roger N. Morris, Edward D. Rickert, William (Bill) J. Toman, Richard B. Davis

04/06/21 – Article "To Be or Not to 340B: HHS Issues Advisory Opinion and New GAO Report Sheds Light on HRSA’s Enforcement Pullback" Pratt's Government Contracting Law Report By: Brenda M. Maloney Shafer, Richard B. Davis

01/05/21 – Blog The End of a Wild Year for 340B: HHS Issues Advisory Opinion and New GAO Report Sheds Light on HRSA’s Enforcement Pullback To Be Or Not To 340B Brenda M. Maloney Shafer, Richard B. Davis

12/02/20 – Newsletter New Wisconsin Patient Consultation Rule Affecting Resident and Non-Resident Pharmacies to Take Effect on January 1, 2021 Health & Life Sciences Alert Susan Brichler Trujillo, Richard B. Davis, Christopher M. Guthrie

09/30/20 – Article "Drug Manufacturers Cut Off 340B Pricing for Contract Pharmacies" State Bar of Wisconsin's Health Law Blog Richard B. Davis

08/20/20 – Newsletter AstraZeneca to Cut Off 340B Pricing for Contract Pharmacies on October 1 Health & Life Sciences Alert Brenda M. Maloney Shafer, Richard B. Davis

07/10/20 – Newsletter Notice to Covered Entities: Manufacturer Seeking 340B Claims Data To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis

05/20/20 – Presentation "Multistate Pharmacy Jurisprudence Review" Medical College of Wisconsin School of Pharmacy By: Roger N. Morris, Richard B. Davis

04/30/20 – Newsletter CMS Publishes 340B Drug Acquisition Cost Survey: Respond by May 15, 2020 To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis

03/23/20 – Newsletter HRSA Unveils New 340B Flexibilities During COVID-19 Crisis To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis

02/03/20 – Newsletter GAO Report Suggests Increased Oversight of 340B Program To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis

01/14/20 – Newsletter The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies: Board Submits Final Rule Draft Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis, Christopher M. Guthrie

11/25/19 – Newsletter Board’s Economic Impact Analysis Disputes Industry Submissions, Board Advances Proposed Rule Without Changes Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis

11/19/19 – Newsletter Results of Economic Impact Discussion: The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis

11/05/19 – Newsletter The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies: Potential Relief for Mail Order Pharmacies? Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis

10/30/19 – Newsletter The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis

10/25/19 – Newsletter Update on Status of Proposed Wisconsin Patient Counseling Rule that Will Impact Mail Order Pharmacies Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis

10/14/19 – Newsletter Applications Now Available for Alaska's New Licensing Categories and Prescription Standards Health & Life Sciences Alert Susan B. Trujillo, Nicholas H. Meza, Richard B. Davis

09/18/19 – Newsletter New PBM State Laws Indicate a Shifting Battlefront over 340B Program Drug Pricing To Be or to Not to 340B Blog Brenda M. Shafer, Richard B. Davis

08/06/19 – Newsletter Interesting 340B Takeaways from 2020 OPPS Proposed Rule To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis, Benjamin A. Lockwood

08/01/19 – Newsletter 503B Loses Federal Preemption Argument, Appeals to Ninth Circuit Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis, Benjamin A. Lockwood

07/18/19 "The 340B Drug Pricing Program Year in Review: What's Smoke and What's Fire in a Changing Landscape" Quarles & Brady Pharmacy Law Symposium

07/09/19 – Blog 340B Litigation Updates and Other Program Developments To Be or Not to 340B Brenda M. Shafer, Richard B. Davis

03/19/19 – Newsletter The President’s 2020 Budget Keeps 340B Program in the Spotlight To Be or Not to 340B Brenda Maloney Shafer, Richard Davis

02/25/19 – Blog "CVS Caremark Reverses Planned Payment Cuts to 340B Providers" To Be or Not to 340B Brenda M. Shafer, Richard B. Davis

01/29/19 – Blog "We're 340Back! Review of Major Developments to the 340B Program" To Be or Not to 340B Brenda M. Shafer and Richard B. Davis